Dear Healthcare Professional Letter to physicians concerning safe use of Myfortic (mycophenolic acid)
Novartis Hrvatska d.o.o., in cooperation with the Agency for Medicinal Products and Medical Devices, on 6 July 2009, sent a Dear Healthcare Professional Letter to prescribing physicians in order to inform them about the latest data on safe use of Myfortic 360 mg film-coated gastro-resistant tablets (mycophenolic acid).
The purpose of the Letter is to inform the physicians about the latest safety data on medicinal product containing mycophenolic acid as active substance, including special warnings regarding the increased susceptibility to infection, increased risk of developing lymphomas and other malignancies as well as on the precautions for use of the medicinal product during pregnancy.
The Agency for Medicinal Products and Medical Devices approved the new safety information and included them in the Summary of Product Characteristics and the Patient Information Leaflet.
The full text of the letter with the Summary of Product Characteristics can be found below (in Croatian):
"Important information about prescribing Myfortic® (mycophenolic acid) film-coated gastro-resistant tablet"